Shares of Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Get Free Report) crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.22 and traded as low as $0.1411. Northwest Biotherapeutics shares last traded at $0.1535, with a volume of 11,162,504 shares trading hands.
Northwest Biotherapeutics Price Performance
The stock’s fifty day moving average is $0.20 and its 200-day moving average is $0.22. The stock has a market capitalization of $284.78 million, a PE ratio of -0.01 and a beta of -0.63.
Northwest Biotherapeutics Company Profile
Northwest Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of cancer. The company’s proprietary platform harnesses patient-derived dendritic cells to present tumor-specific antigens and stimulate a targeted immune response. By tailoring each vaccine to the individual patient’s tumor profile, the approach aims to improve outcomes and reduce off-target toxicity associated with conventional therapies.
The company’s lead candidate, DCVax®-L, is designed for patients with newly diagnosed or recurrent glioblastoma multiforme (GBM) and has advanced through a global Phase III clinical trial.
Recommended Stories
- Five stocks we like better than Northwest Biotherapeutics
- Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop
- Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs?
- The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story
- Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-american-depositary-shares-logo-1200x675.png){kind=logo}
